A5064075793- Rheumatoid Arthritis Research and Therapies
- Biosimilars and Bioanalytical Methods
- Autoimmune and Inflammatory Disorders Research
- Systemic Lupus Erythematosus Research
- Chronic Lymphocytic Leukemia Research
- Psoriasis: Treatment and Pathogenesis
- Monoclonal and Polyclonal Antibodies Research
- Spondyloarthritis Studies and Treatments
- Surfactants and Colloidal Systems
- Lymphoma Diagnosis and Treatment
- Photosynthetic Processes and Mechanisms
- Pharmaceutical studies and practices
- thermodynamics and calorimetric analyses
- Mesoporous Materials and Catalysis
- Hepatitis C virus research
- Antibiotic Resistance in Bacteria
- Lipid Membrane Structure and Behavior
- Inflammatory mediators and NSAID effects
- Liver Disease Diagnosis and Treatment
- Health Systems, Economic Evaluations, Quality of Life
- Respiratory viral infections research
- Pneumonia and Respiratory Infections
- Lipid metabolism and biosynthesis
- Chronic Myeloid Leukemia Treatments
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Centrum Medyczne iMed24
2017-2025
Chang Gung University
2021-2023
Chang Gung Memorial Hospital
2020-2023
Jagiellonian University
2013-2016
Silesian University of Technology
2013-2015
Nicolaus Copernicus University
2014
Universidad de Valladolid
2013
National Cheng Kung University
2007-2008
Wojskowy Instytut Medyczny
2006-2007
Polish Academy of Sciences
2003-2006
To assess the effect of baricitinib on patient-reported outcomes (PROs) in patients with active rheumatoid arthritis and an inadequate response to methotrexate (MTX).In this double-blind phase 3 study, were randomised 3:3:2 placebo (n=488), 4 mg once daily (n=487), or adalimumab 40 biweekly (n=330) background MTX. PROs included SF-36, EuroQol 5-D (EQ-5D) index scores visual analogue scale, Functional Assessment Chronic Illness Therapy-Fatigue (FACIT-F), Health Questionnaire-Disability Index...
This study aimed to demonstrate the interchangeability of biosimilar CT-P17 and European Union reference adalimumab (EU-adalimumab) in a repeated-switch scenario. In this ongoing, randomized, double-blind, active-controlled, phase 3 study, adults with moderate-to-severe plaque psoriasis received 80 mg EU-adalimumab on day 1, then 40 1 week later every other until 11. At 13, patients were randomized (1:1, via an interactive web response system) continue ("continuous" group) or undergo...
Pseudomonas aeruginosa intestinal carriage rates are significantly higher in immunosuppressed individuals and hospitalized patients who therefore have increased risk of infections antibiotic-associated diarrhea. To combat dysbiosis decolonize P. from gastrointestinal tract, we investigated the anti-adherence gut microbiota modulation properties marine prebiotic fucoidans.Proteomic analysis culture supernatant was performed by LC-MS/MS. Using lectin-based enzyme-linked immunosorbent assay,...
Abstract Background To demonstrate equivalent efficacy of the proposed high-concentration (100 mg/ml), citrate-free adalimumab biosimilar CT-P17 to European Union-approved (EU-adalimumab) in subjects with active rheumatoid arthritis (RA). Methods This randomized, double-blind phase III study ( ClinicalTrials.gov , NCT03789292) randomized (1:1) RA at 52 centers receive or EU-adalimumab 40 mg subcutaneously every 2 weeks until week 52. Results 24 are reported here. The primary endpoint was 20%...
Abstract BACKGROUND Biotrickling filtration is one of the most promising biotechnologies for off‐gas treatment. However, gas–liquid mass transfer limitations constitute important drawback biotrickling filters (BTFs) when treating hydrophobic pollutants. Oxygen might also arise soluble pollutants at high loading rates. In present study, an easy‐to‐implement method characterization in BTFs based on dissolved oxygen measurements was investigated . RESULTS k L a values range 30–300 h −1 were...
Objectives To identify the first time point of an MRI-verified response to certolizumab pegol (CZP) therapy in patients with rheumatoid arthritis (RA). Methods Forty-one active RA despite disease-modifying antirheumatic drug were randomised 2:1 CZP (CZP loading dose 400 mg every 2 weeks at 0–4; 200 6–16) or placebo→CZP (placebo 0–2; 2–6; 8–16). Contrast-enhanced MRI one hand and wrist was acquired baseline (week 0) 1, 2, 4, 8 16. All six points read simultaneously, blinded time, using...
CT-P43 is a candidate ustekinumab biosimilar in clinical development. This paper aims to demonstrate equivalent efficacy of originator adults with moderate severe plaque psoriasis. double-blind, phase III trial randomised patients (1:1) receive subcutaneous or (45/90 mg for baseline body weight ≤ 100 kg/> kg) at week 0 and 4 Treatment Period I. Prior 16 dosing II, receiving were re-randomised continue switch CT-P43; initially continued (at weeks 16, 28 40). The primary endpoint the was mean...
Objective. To evaluate the efficacy and safety of poseltinib (formerly LY3337641/HM71224), an irreversible covalent inhibitor Bruton’s tyrosine kinase in a 2-part, phase II trial (RAjuvenate; ClinicalTrials.gov : NCT02628028 ) adults with active rheumatoid arthritis (RA). Methods. In Part A, 36 patients mildly RA were randomized 1:1:1:1 to oral 5, 10, or 30 mg placebo once daily for 4 weeks assess tolerability. No signals precluded moving B, where 250 moderate-to-severe 5 (n = 63), 10 62),...
Objective. Evaluate safety and efficacy of intravenous (IV) golimumab (GOL) in patients with active ankylosing spondylitis (AS) through 1 year. Methods. A total 208 were randomized to IV infusions GOL 2 mg/kg (n = 105) at weeks 0, 4, every 8 thereafter or placebo 103) 12, then crossover 16, 20, Week 52. Efficacy was assessed using the Assessment Spondyloarthritis international Society (ASAS) criteria, Ankylosing Spondylitis Disease Activity Score (ASDAS), Bath Index (BASDAI), Functional...
Acinetobacter baumannii is an important nosocomial pathogen. To better understand the role of CsuA/BABCDE pilus A. in virulence, bacterial biofilm formation, adherence and carbohydrate-mediated inhibition were conducted.CsuA/BABCDE pilus-producing (abbreviated Csu pilus) operon ATCC17978 was cloned for analysis formation on abiotic plastic plate, to respiratory epithelial human A549 cells inhibition. The carbohydrates used included monosaccharides, pyranosides, mannose-polymers.The expressed...
To compare the safety and efficacy of switching from reference adalimumab to biosimilar CT-P17 with continuing adalimumab/CT-P17 in active RA.This double-blind, phase III study randomized (1:1) subjects RA receive 40 mg (100 mg/ml) or European Union-sourced subcutaneously every 2 weeks (Q2W) until week (W) 24 [treatment period (TP) 1]. Thereafter, receiving were continue switch W26 (both Q2W W48; TP2). Subjects TP1 continued CT-P17. W0-W24 results previously reported; we present W26-W52...
Gold nanoparticles (Au NPs) were prepared and surface-modified by mercaptosuccinic acid (MSA) to render a surface with carboxylic groups (MSA-Au). Octadecylamine (ODA) was used as template monolayer adsorb the Au NPs dispersed in subphase. The effect of MSA concentration on incorporation ODA relevant behavior mixed studied using pressure-area (pi-A) isotherm transmission electron microscopy (TEM) observations. experimental results showed that adsorbed density is low without modification MSA....
Polystyrenesulfonate acid (PSS) and alkyltrimethylammonium bromide (CnTAB, n = 8, 14, or 18) were dissolved in a chloroform/methanol solution cospread on an air/water interface. The surfactant−polyelectrolyte interaction leads to the formation of hydrophobic complexes which are able spread well at effects surfactant chain length surfactant/polymer ratio characteristics mixed monolayers studied terms surface pressure−area (π−A) isotherm, area relaxation, hysteresis behavior as morphology...
Objectives To demonstrate efficacy equivalence of CT-P47 and EU-approved reference tocilizumab (r-TCZ) in patients with rheumatoid arthritis (RA). Methods This double-blind, phase III study randomised (1:1) to receive or r-TCZ (8 mg/kg) every 4 weeks until week 20 during treatment period (TP) 1. Prior 24 dosing, receiving were continue switch CT-P47; continued (TP2, 8 mg/kg 48). The dual primary endpoints (for different regulatory requirements) mean changes from baseline Disease Activity...
Quasi equilibrated temperature programmed desorption and adsorption (QE-TPDA) of hexane cyclohexane was applied for characterization zeolites 5A, ZSM-5, 13X, Y, NaMOR ordered mesoporous silicas MCM-41, MCM-41/TMB, SBA-15 HMS. Similar QE-TPDA profiles with a single maximum were observed the wide pore zeolites. No zeolite 5A ZSM-5 found, while two-step these values enthalpy entropy obtained by fitting Langmuir model functions X Y. For larger differences in parameters found. A peak found at low...
BackgroundThe most severe form of pneumococcal disease is invasive (IPD), including empyema, sepsis and meningitis. Thomsen-Friedenreich antigen (TA; Galβ1-3GalNAc) activation known to be a predictor Streptococcus pneumoniae-associated hemolytic uremic syndrome (Sp-HUS). There have been limited data correlate TA overall severity IPD in children. The study aimed prove the positive correlation between demonstrate trend level during course.MethodsWe retrospectively reviewed medical records from...